The presence of activating mutations in a small number of patients, as well as evidence of copy number gain and mRNA and protein overexpression, all suggest the importance of HER2 to the oncogenic phenotype of a subset of bladder cancers, and likely represents a therapeutic opportunity in a selected patients with locally advanced and metastatic UC. This evidence concerns the gene ERBB2 and urinary bladder cancer.